The Company has submitted a supplemental New Drug Application (sNDA) seeking the approval of revumenib for the treatment of R/R mNPM1 AML. The sNDA has been granted Priority Review by the FDA and ...
Here’s what experts are learning about this chaotic period leading up to menopause—including what causes its symptoms, when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback